APA (7th ed.) Citation

Böck, S., Vehling-Kaiser, U., Waldschmidt, D., Kettner, E., Märten, A., Winkelmann, C., . . . Heinemann, V. (2010). Erlotinib 150 mg daily plus chemotherapy in advanced pancreatic cancer: An interim safety analysis of a multicenter, randomized, cross-over phase III trial of the "Arbeitsgemeinschaft Internistische Onkologie". Anti-cancer drugs, 21(1), . https://doi.org/10.1097/CAD.0b013e32833123ed

Chicago Style (17th ed.) Citation

Böck, Stefan, et al. "Erlotinib 150 Mg Daily Plus Chemotherapy in Advanced Pancreatic Cancer: An Interim Safety Analysis of a Multicenter, Randomized, Cross-over Phase III Trial of the "Arbeitsgemeinschaft Internistische Onkologie"." Anti-cancer Drugs 21, no. 1 (2010). https://doi.org/10.1097/CAD.0b013e32833123ed.

MLA (9th ed.) Citation

Böck, Stefan, et al. "Erlotinib 150 Mg Daily Plus Chemotherapy in Advanced Pancreatic Cancer: An Interim Safety Analysis of a Multicenter, Randomized, Cross-over Phase III Trial of the "Arbeitsgemeinschaft Internistische Onkologie"." Anti-cancer Drugs, vol. 21, no. 1, 2010, https://doi.org/10.1097/CAD.0b013e32833123ed.